Evidence map›Paper›PMID 40704651›Full record

ArticleFuture oncology (London, England)2025

Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study.

Mehmet Ali Nahit Sendur, Nuri Karadurmus, Irfan Cicin, Mahmut Gumus, Umut Demirci, Ozgur Ozyilkan, Muhammet Ali Kaplan, Sema Sezgin Goksu, Feyyaz Ozdemir, Cagatay Arslan and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mehmet Ali Nahit SendurDepartment of Medical Oncology, Ankara Yıldırım Beyazıt University and Ankara Bilkent City Hospital, Ankara, Turkiye.ORCID 0000-0001-7021-6139
Nuri KaradurmusDepartment of Medical Oncology, Gülhane Training and Research, Ankara, Turkiye.ORCID 0000-0003-3291-8062
Irfan CicinDepartment of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkiye.ORCID 0000-0002-7584-3868
Mahmut GumusDepartment of Medical Oncology, Istanbul Medeniyet University Hospital, İstanbul, Turkiye.ORCID 0000-0003-3550-9993
Umut DemirciDepartment of Medical Oncology, Memorial Ankara Hospital, Ankara, Turkiye.ORCID 0000-0002-4833-6721
Ozgur OzyilkanDepartment of Medical Oncology, Adana Başkent University Hospital, Adana, Turkiye.ORCID 0000-0001-8825-4918
Muhammet Ali KaplanDepartment of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Turkiye.ORCID 0000-0003-0882-0524
Sema Sezgin GoksuDepartment of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkiye.ORCID 0000-0002-1222-0444
Feyyaz OzdemirDepartment of Medical Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkiye.ORCID 0000-0001-6980-2800
Cagatay ArslanDepartment of Medical Oncology, İzmir Medical Point Hospital, İzmir, Turkiye.ORCID 0000-0002-3783-7432
Basak Oyan UlucDepartment of Medical Oncology, Acıbadem Altunizade Hospital, Instabul, Turkiye.ORCID 0000-0002-6623-6273
Erdem GokerDepartment of Medical Oncology, Ege University Faculty of Medicine, İzmir, Turkiye.ORCID 0000-0001-6180-713X
Muhammed Mustafa OksuzokyarMSD Turkiye, İstanbul, Turkiye.ORCID 0009-0008-3391-4526
Yasemin EsenMSD Turkiye, İstanbul, Turkiye.ORCID 0009-0004-2047-6521
Mert BatumMSD Turkiye, İstanbul, Turkiye.ORCID 0009-0008-8108-5590
Milan van RheenanMSD Netherlands, Haarlem, Netherlands.ORCID 0009-0003-1454-0913
Bernadette PoellingerMSD Germany, Munich, Germany.ORCID 0009-0008-3495-3930

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis national, multicenter, retrospective, non-interventional real-world evidence study aimed to address patient characteristics and systemic treatment practices of metastatic non-small cell lung cancer (mNSCLC) patients in Türkiye. RESEARCH DESIGN AND

methodsOver 6 months, 636 adults with mNSCLC at 12 Turkish oncology centers provided retrospective data.

resultsAdenocarcinoma was the most common histology, with 95% having distant bone metastases and 64.8% having no comorbidities. The most frequently administered first-line therapy was combination chemotherapy followed by targeted therapy and immunotherapy. Overall, 55.5-69.3% of patients were tested for ALK, EGFR, ROS1, and PD-L1.

conclusionsBiomarker screening in mNSCLC patients in Türkiye was suboptimal compared to other countries, especially in public hospitals.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsPractice Patterns, Physicians'AdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansImmunotherapyMaleMiddle AgedMolecular Targeted TherapyRetrospective StudiesTurkeyBiomarkers, Tumorbiomarker assessmentMetastatic non-small cell lung cancerobservational studyreal-world evidenceretrospectivetreatment patterns

Identifiers

PMID40704651
PMCPMC12330250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.